Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.8999
USD
|
+1.00%
|
|
+1.75%
|
-6.50%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
124.6
|
302.5
|
558.5
|
163.8
|
85.56
|
80.66
|
-
|
-
|
Enterprise Value (EV)
1 |
124.6
|
302.5
|
558.5
|
163.8
|
85.56
|
80.66
|
80.66
|
80.66
|
P/E ratio
|
-1
x
|
-6.9
x
|
-3.15
x
|
0.96
x
|
-1.03
x
|
-1.06
x
|
-0.94
x
|
-1.31
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.95
x
|
56.3
x
|
282
x
|
4.84
x
|
264
x
|
10.1
x
|
37.6
x
|
2.54
x
|
EV / Revenue
|
9.95
x
|
56.3
x
|
282
x
|
4.84
x
|
264
x
|
10.1
x
|
37.6
x
|
2.54
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-5.56
x
|
-3.49
x
|
-
|
-1.1
x
|
-1.09
x
|
-1.19
x
|
FCF Yield
|
-
|
-
|
-18%
|
-28.7%
|
-
|
-90.5%
|
-91.7%
|
-84.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
61,382
|
62,634
|
86,862
|
88,045
|
88,891
|
89,630
|
-
|
-
|
Reference price
2 |
2.030
|
4.830
|
6.430
|
1.860
|
0.9625
|
0.8999
|
0.8999
|
0.8999
|
Announcement Date
|
2/25/20
|
2/25/21
|
3/1/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
12.52
|
5.372
|
1.979
|
33.82
|
0.324
|
8.004
|
2.143
|
31.74
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-116
|
-44.52
|
-90.51
|
-60.39
|
-93.06
|
-85.44
|
-99.07
|
-79.14
|
Operating Margin
|
-926.46%
|
-828.67%
|
-4,573.52%
|
-178.53%
|
-28,723.77%
|
-1,067.37%
|
-4,623.29%
|
-249.35%
|
Earnings before Tax (EBT)
1 |
-112.6
|
-43.52
|
-173.2
|
172.2
|
-82.1
|
-76.59
|
-92.72
|
-73.99
|
Net income
1 |
-112.6
|
-43.52
|
-173.2
|
172.2
|
-82.1
|
-76.59
|
-92.72
|
-71.13
|
Net margin
|
-899.24%
|
-810.16%
|
-8,753.71%
|
509.01%
|
-25,337.96%
|
-956.83%
|
-4,326.73%
|
-224.12%
|
EPS
2 |
-2.030
|
-0.7000
|
-2.040
|
1.940
|
-0.9300
|
-0.8486
|
-0.9557
|
-0.6886
|
Free Cash Flow
1 |
-
|
-
|
-100.4
|
-46.94
|
-
|
-73
|
-74
|
-68
|
FCF margin
|
-
|
-
|
-5,075.19%
|
-138.77%
|
-
|
-912.01%
|
-3,453.33%
|
-214.25%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
2/25/21
|
3/1/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.107
|
0.046
|
0.015
|
0.44
|
32.56
|
0.814
|
0.283
|
0.026
|
0.011
|
0.004
|
0.06
|
0.06
|
0.06
|
0.06
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-18.6
|
-39.53
|
-24.77
|
-23.45
|
11.65
|
-23.81
|
-24.22
|
-21.35
|
-26.69
|
-20.81
|
-21.76
|
-22.72
|
-23.43
|
-20.37
|
Operating Margin
|
-17,383.18%
|
-85,939.13%
|
-165,140%
|
-5,328.86%
|
35.77%
|
-2,925.55%
|
-8,557.6%
|
-82,107.69%
|
-242,627.27%
|
-520,250%
|
-36,273.62%
|
-37,858.33%
|
-39,043.88%
|
-33,946.95%
|
Earnings before Tax (EBT)
1 |
-18.56
|
-39.5
|
-24.77
|
-23.47
|
241.5
|
-21.08
|
-21.37
|
-18.58
|
-23.99
|
-18.16
|
-19.15
|
-20.18
|
-21
|
-18.49
|
Net income
1 |
-18.56
|
-39.5
|
-24.77
|
-23.47
|
241.4
|
-20.96
|
-21.37
|
-18.58
|
-23.99
|
-18.16
|
-19.15
|
-20.18
|
-21
|
-18.49
|
Net margin
|
-17,345.79%
|
-85,865.22%
|
-165,113.33%
|
-5,333.64%
|
741.4%
|
-2,574.94%
|
-7,551.94%
|
-71,446.15%
|
-218,054.55%
|
-454,025%
|
-31,916.12%
|
-33,641.12%
|
-35,008.05%
|
-30,811.12%
|
EPS
2 |
-0.2100
|
-0.4500
|
-0.2800
|
-0.2700
|
2.750
|
-0.2400
|
-0.2400
|
-0.2100
|
-0.2700
|
-0.2000
|
-0.2150
|
-0.2217
|
-0.2350
|
-0.1983
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/1/22
|
5/16/22
|
8/8/22
|
11/3/22
|
3/2/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/29/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-100
|
-46.9
|
-
|
-73
|
-74
|
-68
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.16
|
0.06
|
0.21
|
0.07
|
-
|
0.04
|
0.05
|
0.05
|
Capex / Sales
|
1.26%
|
1.08%
|
10.46%
|
0.21%
|
-
|
0.5%
|
2.33%
|
0.16%
|
Announcement Date
|
2/25/20
|
2/25/21
|
3/1/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
0.8999
USD Average target price
7
USD Spread / Average Target +677.86% Consensus |
1st Jan change
|
Capi.
|
---|
| -6.50% | 80.66M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|